This study is currently not accepting new patients, but might later
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
Summary
- Eligibility
- for people ages 1-25 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Michelle Hermiston
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Michelle Hermiston
Associate Professor, Pediatrics. Authored (or co-authored) 87 research publications.
Details
- Status
- currently not accepting new patients, but might later
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Novartis Pharmaceuticals
- ID
- NCT03876769
- Phase
- Phase 2
- Study Type
- Interventional
- Last Updated